The Quiet Drug Discovery Revolution: How Protein Degraders Are Cracking the Undruggable Proteome in 2026

For three decades, drug discovery operated under a constraint that limited what medicine could touch. Roughly four out of every five human proteins lack the deep catalytic pockets that small molecule inhibitors need to bind. Cancer-driving transcription factors, scaffolding proteins, mutant tau, alpha-synuclein, oncogenic KRAS in its inactive state. All sat on the wrong side of a wall called the undruggable proteome.

Presented By Our Partners

That wall is now coming down. At the 2026 American Society of Clinical Oncology meeting underway this week in Chicago, a quiet but unmistakable shift is visible across the abstracts and late-breaking sessions. Targeted protein degradation, the strategy of removing disease-driving proteins rather than blocking them, has stopped being a laboratory curiosity. It is producing late-stage clinical data, generating molecular glue platforms, and converging with artificial intelligence in ways that could redefine pharmaceutical R&D over the next decade.

This is a deep dive on where the field stands, what the 2026 readouts actually show, and why a generation of investors, biologists, and clinicians are now describing degraders as the most important modality since monoclonal antibodies.

From Inhibition to Elimination

Conventional small molecule drugs work by occupying an active site. A statin slots into HMG-CoA reductase. A kinase inhibitor lodges in the ATP pocket of a kinase. The drug stays bound, and the protein cannot function while it is occupied. The strategy is elegant when a protein has a usable pocket. It collapses when the protein is a flat surface, a transcription factor without a binding cleft, or a misfolded aggregate driving neurodegeneration.

Targeted protein degradation rewrites the question. Instead of asking how to block a protein, the field asks how to delete it. The body already has a sophisticated system for removing damaged or unwanted proteins. It is called the ubiquitin proteasome system, and it tags proteins for destruction by attaching small ubiquitin molecules to them, after which the proteasome chews them up.

The breakthrough, first articulated by Craig Crews at Yale in a 2001 Proceedings of the National Academy of Sciences paper, was that medicinal chemists could hijack this system. A heterobifunctional molecule, a chimera with two business ends connected by a linker, could grab a disease-causing protein on one side and an E3 ubiquitin ligase on the other. The ligase would mistake the disease protein for cellular garbage and tag it for destruction. Crews coined the term PROTAC, proteolysis targeting chimera. The mechanism was beautiful. For fifteen years the chemistry was so difficult that almost nobody believed it would reach the clinic.

In 2026, more than thirty PROTACs and related degraders are in human trials, and the first late-stage Phase 3 readouts are arriving.

The Vepdegestrant Moment

The story for the broader field changed in late 2024 when Arvinas and Pfizer reported topline data from VERITAC-2, a Phase 3 trial of vepdegestrant in heavily pretreated, estrogen receptor positive, HER2 negative metastatic breast cancer. The drug, also called ARV-471, is the first PROTAC to advance to a registrational study. It targets the estrogen receptor itself, a transcription factor that fulvestrant has been targeting through degradation by injection for two decades, but with limitations of bioavailability and route of administration.

In the subset of patients carrying ESR1 mutations, vepdegestrant produced a median progression-free survival of 5.0 months versus 2.1 months for fulvestrant, a 43 percent reduction in the risk of progression or death. The intent-to-treat population, mixing ESR1 wild type and mutated patients, did not separate. That nuance matters. ESR1 mutations are the most common acquired resistance mechanism in metastatic ER positive breast cancer, and vepdegestrant has now become the first oral, biomarker-defined PROTAC therapy on a path to regulatory submission. ASCO 2026 is featuring expanded follow up data this week, with overall survival readouts expected by year end.

The signal is what matters. A PROTAC, given as a pill, just outperformed the standard of care in a defined molecular subgroup. The chemistry works. The pharmacology works. Regulators are paying attention. Companies behind the next wave, including Kymera Therapeutics, Nurix Therapeutics, C4 Therapeutics, Foghorn Therapeutics, and Monte Rosa Therapeutics, have seen their pipelines re-rated.

The BTK Story and What It Tells Us About Resistance

Beyond breast cancer, the most watched degrader program in oncology in 2026 is the BTK degrader race. Bruton’s tyrosine kinase, the central B cell signaling node, has been a transformative target in chronic lymphocytic leukemia and mantle cell lymphoma since ibrutinib’s approval in 2013. But two related problems have plagued BTK inhibitors. Patients develop resistance through BTK mutations such as C481S that prevent covalent binding. And a newer class of inhibitors, called noncovalent BTK inhibitors like pirtobrutinib, are themselves now seeing resistance mutations such as L528W.

A degrader bypasses both. By removing BTK from the cell entirely rather than blocking its catalytic site, mutations that prevent drug binding lose their evolutionary advantage. There is no active site to mutate around if the entire protein is gone.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Nurix Therapeutics’s NX-5948, also known as bexobrutideg, has produced response rates in the range of 75 to 80 percent in heavily pretreated CLL patients who have failed both covalent and noncovalent BTK inhibitors, according to data presented at the American Society of Hematology in December 2025 and expanded readouts at ASCO 2026. BeiGene’s BGB-16673 has shown similar early signals. The strategic implication is striking. For the first time, oncologists may have a therapy that works after BTK resistance has emerged, opening a new line of therapy for patients who previously had few options.

Molecular Glues, the Lighter Cousin

PROTACs are heavy molecules. With two protein-binding warheads and a linker, they often exceed 700 daltons, which complicates oral bioavailability and tissue penetration. A parallel branch of the field, molecular glues, uses smaller, drug-like compounds that induce a productive interface between an E3 ligase and a target protein without explicitly binding both. Lenalidomide, the multiple myeloma drug, turned out, in retrospect, to be the first widely used molecular glue. It binds cereblon, the substrate adapter of a ubiquitin ligase complex, and recruits transcription factors IKZF1 and IKZF3 for destruction.

The new generation of molecular glues is being designed deliberately rather than discovered serendipitously. Monte Rosa Therapeutics’s GSPT1 degrader MRT-2359, in solid tumors driven by MYC, has produced disease control in MYC-amplified non small cell lung cancer in early Phase 1 expansion cohorts. C4 Therapeutics has multiple cereblon-recruiting molecular glues in trials. Bristol Myers Squibb’s CELMoDs, the next generation of cereblon modulators, have reshaped multiple myeloma treatment. The category is no longer a footnote. Researchers including Benjamin Ebert at Dana-Farber and Eric Fischer at the Broad Institute have published structural and computational work that turns molecular glue discovery from luck into design.

The AI Angle

Drug design at this scale would have been impossible without computation. A PROTAC requires the simultaneous optimization of three things. The warhead binding to the target. The E3 ligase binder. And, critically, the linker geometry that allows the ternary complex of target, drug, and ligase to form in a way that positions the target lysine residues correctly for ubiquitin transfer. That third constraint is brutal. Linker length, rigidity, and exit vector all matter, and minor changes can swing a candidate from highly potent degrader to inert binder.

Several 2026 advances have accelerated this. Generative models trained on ternary complex crystal structures, including work from the labs of David Baker at the Institute for Protein Design and the team at Isomorphic Labs, can now propose linker designs and predict cooperativity with growing accuracy. AlphaFold 3, released in 2024 and refined through 2025 and 2026, can model the multimeric complexes that PROTACs induce, although protein motion remains a frontier. MIT researchers published a Cell paper in early 2026 using diffusion models trained on cryo electron microscopy ensembles to predict the conformational ensembles of target proteins, an approach that may close the dynamic gap that static structures miss.

Roche acquired Recursion Pharmaceuticals’ degrader capabilities through its earlier Exscientia integration. Pfizer expanded its Arvinas partnership. Eli Lilly built an internal protein degradation platform after acquiring Loxo’s chemistry expertise. AI native biotech companies including Atomwise, Iambic Therapeutics, and Insitro all now describe protein degradation as a core capability. The industry has decided that the future of drug discovery looks computational and modal in equal measure.

The Neurology Frontier

Oncology is the proving ground. Neurodegeneration may be the bigger prize. Tau, alpha synuclein, mutant huntingtin, and TDP-43, the protein aggregates that drive Alzheimer’s, Parkinson’s, Huntington’s, and amyotrophic lateral sclerosis, have resisted classical drug discovery for the same reason. They lack pockets, they aggregate into structures that vary across patients, and they accumulate slowly over decades.

A degrader strategy fits the biology. If you can remove tau before it aggregates, or accelerate clearance of alpha synuclein from neurons, you may slow or reverse disease. Several programs are now in the clinic. Arvinas’s ARV-102, a brain-penetrant LRRK2 degrader for Parkinson’s disease and progressive supranuclear palsy, completed its first Phase 1 healthy volunteer study with biomarker engagement and is moving into patient cohorts in 2026. Nurix’s NX-1607 program in oncology has spawned interest in CBL-B degraders for autoimmunity. Foghorn Therapeutics’s FHD-909, a selective BRG1 degrader for SMARCA4 mutant lung cancer, is in active dose escalation.

The neuroscience challenge is delivery. Most PROTACs do not cross the blood brain barrier. The next generation of degraders is being designed with central nervous system penetrance from the start, often by reducing molecular weight, increasing lipophilicity within Lipinski limits, and avoiding charged ligase binders. A subset of laboratories is also exploring delivery via lipid nanoparticles and conjugates, drawing on insights from the messenger RNA vaccine era.

The Manufacturing and Pharmacology Puzzle

Degraders create new translational problems. Because the drug acts catalytically, repeatedly tagging proteins for destruction without being consumed, the relationship between drug exposure and pharmacodynamic effect is nonlinear. Standard pharmacokinetic intuitions break down. Investigators including Daniel Nomura at the University of California Berkeley and Mikolaj Slabicki at Dana-Farber have published methods for measuring intracellular degrader concentration and cooperativity in living cells, addressing a measurement gap that delayed earlier programs.

Manufacturing is a second challenge. Heterobifunctional molecules are synthetically complex, often requiring twelve to twenty step convergent syntheses. Process chemistry teams at Arvinas, Kymera, and contract manufacturers are now publishing route designs that reduce step counts and improve yields, which matters for late-stage trials and eventual commercial supply.

A third question is patient selection. The vepdegestrant data already show that biomarker stratification matters. Future PROTACs will likely be approved in defined molecular subgroups rather than broad indications, mirroring the precision oncology playbook that companion diagnostics enabled for tyrosine kinase inhibitors a generation ago. Investors are beginning to model degrader programs more like Tagrisso than like Avastin, narrower labels at higher prices with stronger biomarker positioning.

What ASCO 2026 Is Telling Us This Week

The current ASCO meeting includes more than forty abstracts featuring protein degradation programs across solid and hematologic malignancies. Selected highlights worth watching include the expanded vepdegestrant overall survival follow up in the VERITAC-2 trial, the bexobrutideg CLL update from Nurix, BGB-16673 mantle cell lymphoma data from BeiGene, and early Phase 1 readouts on BCL6 degraders from C4 and Genentech in diffuse large B cell lymphoma.

The Friday late-breaking session will feature combinations. PROTACs paired with immune checkpoint inhibitors. Degraders combined with antibody drug conjugates. The therapeutic logic is straightforward. Remove the resistance node, then layer in the agent that the patient could not tolerate or respond to before. The cardiothoracic and breast cancer tracks alone are dedicating multiple sessions to degrader strategies in 2026, a marked shift from the single satellite symposium that was common just three years earlier.

What This Means For You

If you are a patient with metastatic ER positive breast cancer carrying an ESR1 mutation, ask your oncologist about vepdegestrant access. Approval timelines are aggressive and clinical trial enrollment continues for combination regimens.

If you are a patient with chronic lymphocytic leukemia who has progressed on covalent and noncovalent BTK inhibitors, ask whether your treatment center is enrolling in NX-5948 or BGB-16673 trials. The early data suggest a meaningful new line of therapy.

If you or a family member is at risk for or living with Parkinson’s disease, especially in LRRK2 mutant subtypes, follow the ARV-102 development closely. Trial enrollment may expand to early symptomatic patients in 2027.

If you are an investor in life sciences, recognize that the degrader category has graduated from speculative to commercially meaningful. The leading platform companies, Arvinas, Kymera, Nurix, C4, Foghorn, and Monte Rosa, each have differentiated approaches, and the largest pharmaceutical companies have all moved from observation to active partnership.

If you are a primary care physician or generalist, the practical implication is that degraders will start to enter your clinical context through patients on second and third line therapies. Knowing that an oral pill can degrade a transcription factor is not yet textbook material, but it will be.

The broader meaning is harder to overstate. For most of the modern pharmaceutical era, the medicines we could make were constrained by the proteins our chemistry could touch. The undruggable proteome was not a metaphor. It was a hard ceiling. In 2026, that ceiling is cracking. The science is no longer about whether a degrader can be made. It is about which targets, which patients, and at what scale. A modality that was theoretical when this century began is now generating Phase 3 survival curves. The next decade of drug discovery is being written in real time, and protein degradation is one of its central chapters.

Sources and Further Reading

Vepdegestrant VERITAC-2 trial data, Arvinas and Pfizer, December 2024 topline release and 2026 ASCO follow up. Bexobrutideg NX-5948 data, Nurix Therapeutics, American Society of Hematology December 2025 and ASCO June 2026. BGB-16673 data, BeiGene, ASCO 2026. Original PROTAC concept publication, Sakamoto et al., Crews lab at Yale, Proceedings of the National Academy of Sciences, 2001. Ternary complex structural reviews from the laboratories of Eric Fischer at the Broad Institute and Alessio Ciulli at the University of Dundee. AlphaFold 3 capabilities reviewed in Abramson et al., Nature, 2024. Diffusion model conformational ensemble work, MIT and ASU collaboration, Cell, 2026.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.